RCT: Treatment with Etirinotecan pegol for patients with metastatic breast cancer and brain metastases.

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Commentary on Twitter

Treatment with etirinotecan pegol showed no statistically significant improvement in survival among patients with #BreastCancer & brain metastases, but study represents larged published study for this understudied population. https://t.co/AVKeo1BWQV #BCSM #BTSM

— JAMA Oncology (@JAMAOnc) May 12, 2022